Small companies and academic institutions develop their assets, in most cases, under budget constraints. Still, they have to meet the expectations of future strategic partners or investors in order to be an attractive option for them and to have a chance to get the product onto the market.
AstraZeneca’s anti PD-L1 antibody durvalumab has met the co-primary endpoint in non-small cell lung cancer (NSCLC) in a Phase III trial vs placebo. OS data were not yet available.
London-based immunotherapy developer GammaDelta Therapeutics has hired Paolo Paoletti as Chief Executive Officer. Paoletti was formerly the first appointed President of GSK Oncology, where he was responsible for the overall oncology business.
https://european-biotechnology.com/wp-content/uploads/2024/04/paolo-paoletti.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-05-12 10:49:322017-05-12 10:49:32GammaDelta Therapeutics: New at the top
Drug makers have only until two years from now to make their drugs and packaging counterfeit-resistant. By 9 February, 2019, every prescription drug pack must carry a 2D data matrix code that can be tracked by wholesalers and pharmacists along each stage of the value chain. Additionally, each pack must be sealed with an anti-tampering device. If companies and the NMVOs that handle national databases can’t manage the task, their drugs cannot be sold after the deadline.
https://european-biotechnology.com/wp-content/uploads/2024/04/2017spring-serialisation.jpg6751200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-05-12 09:48:542017-05-12 09:48:54Serialisation: Time is running out
Until recently, aroma compounds were either sourced directly from plants or made from petrochemicals with the help of chemical synthesis processes. Now a handful of biotechnological production approaches are making headway and inroads into the key sector. There haven’t been real breakthroughs in big F&F markets yet, but biotech companies look poised to change the industry forever.
https://european-biotechnology.com/wp-content/uploads/2024/04/2017spring-flavours-fragrances.jpg6751200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-05-12 09:31:002017-05-12 09:31:00Biomanufacturing: The smell of success
Dutch Norgine BV will take-over Merus Labs International Inc. Under the agreement, Norgine will acquire all outstanding shares for US$1.65 per share in cash.
A study conducted by an NIH institute proves Roche’s Avastin is as effective as Regeneron’s Eylea, a drug that costs 30 times more than Roche’s antibody. The rub: Avastin is not approved for use in central retinal vein occlusion (CRVO).
https://european-biotechnology.com/wp-content/uploads/2024/04/Eylea_NEI.jpg8141157Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-05-11 10:23:012017-05-11 10:23:01Cheap Avastin as effective as Eylea in CRVO
Fiasco in Phase III: Roche’s conditionally approved PD-L1 checkpoint inhibitor did not meet the endpoint of overall survival vs chemotherapy in a confirmatory study with pre-treated patients with metastatic urothelial cancer.
https://european-biotechnology.com/wp-content/uploads/2024/04/Roche_PD_L1.png315680Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-05-10 08:01:072017-05-10 08:01:07Roche’s anti-PD-L1 fails in bladder cancer
GMO world market adoption is further growing. GMO cultivation area in 2016 increased to 185.1 million hectares versus 2015 (179.7m hectares), 3% up globally, and from 116,870 in 2015 to 136,363 hectares, 17% up, in the EU.
IP Flash: Cost pressure
OpinionSmall companies and academic institutions develop their assets, in most cases, under budget constraints. Still, they have to meet the expectations of future strategic partners or investors in order to be an attractive option for them and to have a chance to get the product onto the market.
NSCLC: AstraZeneca’s durvalumab meets PFS endpoint
Latest NewsAstraZeneca’s anti PD-L1 antibody durvalumab has met the co-primary endpoint in non-small cell lung cancer (NSCLC) in a Phase III trial vs placebo. OS data were not yet available.
GammaDelta Therapeutics: New at the top
AppointmentsSerialisation: Time is running out
BackgroundDrug makers have only until two years from now to make their drugs and packaging counterfeit-resistant. By 9 February, 2019, every prescription drug pack must carry a 2D data matrix code that can be tracked by wholesalers and pharmacists along each stage of the value chain. Additionally, each pack must be sealed with an anti-tampering device. If companies and the NMVOs that handle national databases can’t manage the task, their drugs cannot be sold after the deadline.
Biomanufacturing: The smell of success
BackgroundUntil recently, aroma compounds were either sourced directly from plants or made from petrochemicals with the help of chemical synthesis processes. Now a handful of biotechnological production approaches are making headway and inroads into the key sector. There haven’t been real breakthroughs in big F&F markets yet, but biotech companies look poised to change the industry forever.
Norgine to acquire Merus
Latest NewsDutch Norgine BV will take-over Merus Labs International Inc. Under the agreement, Norgine will acquire all outstanding shares for US$1.65 per share in cash.
Cheap Avastin as effective as Eylea in CRVO
Latest NewsA study conducted by an NIH institute proves Roche’s Avastin is as effective as Regeneron’s Eylea, a drug that costs 30 times more than Roche’s antibody. The rub: Avastin is not approved for use in central retinal vein occlusion (CRVO).
Roche’s anti-PD-L1 fails in bladder cancer
Latest NewsFiasco in Phase III: Roche’s conditionally approved PD-L1 checkpoint inhibitor did not meet the endpoint of overall survival vs chemotherapy in a confirmatory study with pre-treated patients with metastatic urothelial cancer.
Dermtreat bags €16.2m financing
Latest NewsMucosal inflammation specialist Dermtreat ApS (Copenhagen) has secured a Series A financing worth €16.2m (US$17.7m).
GMO acreage growing
Latest NewsGMO world market adoption is further growing. GMO cultivation area in 2016 increased to 185.1 million hectares versus 2015 (179.7m hectares), 3% up globally, and from 116,870 in 2015 to 136,363 hectares, 17% up, in the EU.